A Prospective Study on the Efficacy and Safety of Different Maintenance Treatment Regimens after 9-Month Course of Budesonide Enteric-Coated Capsules for IgA Nephropathy

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600117860

Enrollment

Unknown

Registered

2026-01-29

Start date

2026-02-01

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA Nephropathy

Interventions

budesonide enteric-coated capsule:NA

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.over the age of 18 years; 2.Renal biopsy-proven primary IgA nephropathy; 3.Completed 9 months of treatment with budesonide enteric-coated capsule; 4.24-hour urine protein>=0.3g/d; 5.eGFR > = 30 mL/min/1.73m^2 when enrolled in this study; 6.Fully understand and be willing to sign the informed consent form;

Exclusion criteria

Exclusion criteria: 1.Patients Who Refuse to Provide Examination Results;

Design outcomes

Primary

Measure	Time frame
Change in urinary protein from baseline;	—

Secondary

Measure	Time frame
microscopic hematuria;24-hour urine protein;End-Stage Renal Disease;Adverse Events;estimated glomerular filtration rate;eGFR,SCr;	—

Countries

China

Contacts

Public ContactXie Jingyuan

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

nephroxie@163.com+86 21 6437 0045

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026